IAM
MDGL icon

Integre Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Integre Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,718
Closed -$499K – 173
2013
Q4 		$499K Buy
2,718
+306
+13% +$56K 0.11% 125
2013
Q3 		$533K Buy
2,412
+617
+34% +$131K 0.14% 105
2013
Q2 		$313K Buy
+1,795
New +$468K 0.08% 155

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Integre Asset Management's MDGL Position: Q1 2014 in Review

Integre Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2014, closing a stake of 2,718 shares — an estimated $499K sold.

Integre Asset Management first reported a position in MDGL in Q2 2013 and held it in 3 quarters. The position peaked at $533K in Q3 2013. 80 funds tracked by Wall St. Rank hold MDGL as of Q1 2014.

  • Integre Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Integre Asset Management sold 2,718 Madrigal Pharmaceuticals shares in Q1 2014, an estimated $499K.
  • Integre Asset Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Integre Asset Management's Madrigal Pharmaceuticals position peaked at $533K in Q3 2013.
  • 80 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2014.

Based on Integre Asset Management's 13F filing for Q1 2014, filed 14 May 2014.